Immunohistochemical evaluation of metallothionein in palatal mucosal cells of mice treated with 4NQO by Aguiar, Maria Cássia Ferreira et al.
E315
Med Oral Patol Oral Cir Bucal 2006;11:E315-8.                                   �                                                  Metallothionein and 4NQO              Oral Medicine and Pathology                                                                �                                                   Metallothionein and 4NQO
© Medicina Oral S.L. Email: medicina@medicinaoral.com
 Immunohistochemical evaluation of metallothionein 
in palatal mucosal cells of mice treated with 4NQO
Maria Cássia Ferreira de Aguiar 1, Daniela Gomes Dos Reis 2, Linaena Mericy da Silva Fonseca 1, Sérgio Vitorino 
Cardoso 1, Jackeline Alvarez Leite 3, Maria Auxiliadora Vieira do Carmo 1
 
(1) DDS, PhD. Department of Oral Pathology, School of Dentistry
(2) graduate student. Department of Oral Pathology, School of Dentistry
(3) DDS, PhD. Department of Biochemistry and Immunology, Biological Sciences Institute. Federal University of Minas Gerais, Brazil
Correspondence:
Prof ª. Dr ª. Maria Cássia Ferreira de Aguiar
Universidade Federal de Minas Gerais
Laboratório de Patologia Experimental 1 (Sala 3201) 
Faculdade de Odontologia 
Av. Antônio Carlos, 6627 
CEP: 31270-901 –  Belo Horizonte (MG), Brazil
E-mail: mcaguiar@odonto.ufmg.br
Received: 16-12-2005   
Accepted: 8-02-2006 Ferreira-de Aguiar MC, Gomes-Dos Reis D, da Silva-Fonseca LM, 
Vitorino-Cardoso S, Alvarez-Leite J,  Vieira-do Carmo MA. Immunohis-
tochemical evaluation of metallothionein in palatal mucosal cells of mice 
treated with 4NQO. Med Oral Patol Oral Cir Bucal 2006;11:E315-8.
© Medicina Oral S. L. C.I.F. B 96689336 - ISSN 1698-6946
ABSTRACT
Objective: Metallothionein (MT) may play a preventive role in various carcinogenic process. 4NQO is an alkaline 
compound and potent mutagen that causes the formation of DNA adducts. The purpose of this study was to evaluate 
the immunoexpression of MT in palatal cells of mice submitted to the carcinogen 4NQO. Study design: C57BL/6 mice 
received applications of 4NQO to palate for periods of 8, 16, 20 and 24 weeks (experimental group). A control group 
received only applications of propylene glycol for the same periods. Subsequently animals of experimental and control 
groups were sacrificed and the palate was histologically analysed and MT immunohistochemistry performed. Results: 
Although morphological atypical features were scant, the expression of MT was higher in the experimental group in 
comparison to controls. There was an amplified induction of MT expression in oral epithelium of mice treated by 
4NQO. Conclusion: These results suggest that MT may act as an endogenous defensive factor against 4NQO in early 
phases of oral carcinogenesis.
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INTRODUCTION
The mechanism involved in transformation of a normal cell 
into a malignant phenotype cell is not completely unders-
tood. Cancer appears after a permanent DNA injury by 
exposure to mutagenic agents or by spontaneous mutation. 
Chemical carcinogens are apparently responsible for the 
majority of human neoplasias and are directly involved in 
the aetiology of oral carcinoma (1, 2). The understanding 
of the early events involved in the pathogenesis of the oral 
squamous cell carcinoma is an important research priority 
(2, 3).
Experimental models have been used to study the effect of 
carcinogens and the evolution of neoplastic changes in oral 
mucosa (4). 4-nitroquinoline 1-oxide (4NQO) is a potent 
chemical carcinogen that exhibits potent and pleiotropic 
carcinogenic effects on various species of animals. 4NQO 
is converted in vivo to 4 hydroxyaminoquinoline 1- oxide 
(4HAQO) and then to a highly reactive metabolite, seryl-
4HAQO-tRNA synthetase to form a guanine and adenine 
adduct. If  these modified bases are not appropriately 
repaired, erroneous genetic information is fixed to induce 
mutation or carcinogenesis (5). 
Wallenius & Lekholm (6) reported that tumours could be 
produced in palatal mucosa of rats after repeated 4NQO 
solution application. Since then, many studies have shown 
induction of squamous cell carcinoma in superior aerodi-
gestive tract sites (e.g. tongue and palate) of experimental 
animals by 4NQO administration (7,8,9). The production 
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of oral mucosal neoplasias in mice with 4NQO has also 
been demonstrated (10,11). 
Metallothioneins (MT) are small non-enzymatic cysteine-
rich proteins that have been considered to protect cells 
against chemical and radiation toxicity (12). The underlying 
mechanism for this function has not been entirely elucidated. 
Its ability to strongly bind and thereby inactivate hazardous 
compounds (e.g. heavy metals, free-radicals, anti-neoplastic 
drugs) has been suggested as fundamental for this action 
(13). Involvement in apoptotic pathways and in the regula-
tion of transcription factor activity has also been proposed 
(14). Other studies on MT in neoplasias investigate its value 
as a prognostic factor (15). Notwithstanding worsening the 
prognosis of cancer, MT ambiguously protects normal cells 
against carcinogens probably by the same obscure mecha-
nisms that render protection to transformed cells (16). This 
action on the normal oral epithelium against genotoxicity 
has not been evaluated yet, but it is known that in normal 
epithelium, MT immunoexpression is restricted to basal 
cells (17). The conservation of  antigenic determinants 
among human, murine and equine species allows the use of 
commercially available antibodies in animal experimental 
research (18).
The purpose of the present study was to examine the effect 
of 4NQO on the tissue morphology and the immunohisto-
chemical expression of MT in oral palatal mucosa of mice 
exposed to that carcinogen. 
MATERIAL AND METHODS
Animals and study design
Forty-eight male C57 Bl/6 mice, 2 months old and weighing 
about 25g were used in this study. Animals were kept in 
plastic cages, six mice per cage, and received water and food 
ad libitum. Ethical approval was obtained from the Scientific 
and Ethical Committee (Ethics Committee in Animal Expe-
rimentation – CETEA - Federal University of Minas Gerais, 
Brazil). The experimental group (24 animals) received the 
4NQO diluted to 0.5% in propylene glycol (PEG) three 
times a week, applied to the palate with a microbrush. The 
control group received only PEG. Six animals of each group 
were killed at different periods (8, 16, 20 and 24 weeks) by 
cervical dislocation, after sedation with commercial ether 
solution, and immediately dissected. Palate was removed, 
stored in 10% formaldehyde for 48 hours and then processed 
and embedded in paraffin. 
Histological and immunohistochemical evaluation
Histological sections of 4 µm were stained by haematoxylin 
and eosin. The slides were evaluated by two expert patholo-
gists (MAVC and MCFA). Immunohistochemical reactions 
for detection of MT were performed with the monoclonal 
antibody E9 (Dako Co., Carpenteria, CA, USA). Sections 
of 4 µm were placed in pretreated slides (3-aminopropyl-
triethoxy-silano). This was followed by deparaffination, 
hydratation, and blocking of intrinsic enzymatic activity 
(peroxidase depleted with 10% H2O2). Then, slides were 
immersed in 1 M ethylenediamine tetraacetic acid (EDTA) 
buffer, pH 9, and submitted to three cycles of 5 minutes in 
a microwave oven. After cooling and washing in distilled 
water, sections were subsequently incubated in primary anti-
body for MT (1:100 dilution), 18 hours at room temperature. 
After washing in distilled water, the slides were incubated in 
secondary biotinylated antibody (Multilink, Biogenex, San 
Ramon, CA, USA) 1:20 peroxidase complex (Dako, 1:100 
dilution) for 30 min. Reactions were revealed by peroxidase 
activity in diaminobenzidine (DAB) chromogene substrate. 
The index for evaluation of MT immunostaining (IMT) was 
constructed based on a percentage of labelled cells among 
200 suprabasal cells. Basal cells were not considered since 
basal layer cells are all positive for MT (17). This number 
was determined previously as the stabilization point of 
a cumulative percentage curve. Comparison of the IMT 
between and within experimental and control groups at 
different time intervals were analysed by Kruskal-Wallis test 
using the software SigmaStat (Jandel Co.; San Rafael, Calif., 
USA). Statistical significance was set at p <0.01.
RESULTS
Histopathological results:
Microscopic findings included a higher frequency of basilar 
hyperplasia, nuclear hyperchromatism and increased mitotic 
activity in the group treated with 4NQO in comparison to 
controls. There were no obvious differences among periods 
of application of the 4NQO. 
Neither carcinomas nor macroscopic changes could be 
observed in the control or experimental groups during the 
period of carcinogen application.
METALLOTHIONEIN IMMUNOHISTOCHE-
MISTRY
Immunohistochemical staining of  MT was sometimes 
observed to be restricted to the nucleus, sometimes to the 
cytoplasm and was sometimes found in both compartments, 
with different intensities between positive cells, showing a 
characteristic mosaic pattern (Figure 1). 
Fig. 1. MT immunostaining in experimental group with suprabasal 
and basal cells showing an intense reaction (streptavidin-biotin-
peroxidase, 400X). 
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Both basal and parabasal cells were stained, but only supra-
basal cells were considered in the counting. Mean IMT was 
always higher in experimental groups compared to controls 
due to higher numbers of immunoreactive cells with both 
cytoplasmic and nuclear staining. There was no clear in-
crease of MT positivity related to the period of carcinogen 
application within groups, however, statistically significant 
differences were observed comparing experimental against 
control groups. MT index in all groups studied at different 
times are summarized in table 1.
DISCUSSION
In the process of carcinogenesis, studies with molecular mar-
kers have allowed for early identification of changes before 
the appearance of the phenotypic dysplastic changes (3). Some 
authors have reported early irreversible changes in the oral 
mucosa of mice during treatment with 4NQO culminating with 
cancer (10,11). In spite of this, the progression of early lesions 
until oral carcinoma was not expected in this work. Considering 
the higher production of TNFα by C57 strain, some authors 
have stressed that carcinomas in this model were produced 
only after 50 weeks of exposure to the carcinogen (19,20). So, 
we focused only in the early alterations of oral palatal mucosa 
treated with 4NQO and their possible correlation with MT 
expression. 
The present study shows amplified induction of MT expre-
ssion in oral epithelium of mice treated by 4NQO although 
it only demonstrated scant histological alterations. In fact, 
cells with initial DNA damage may not show morphological 
alterations for an uncertain period of time. MT protects 
normal cells against carcinogens (16) and this may be the 
reason for an amplified imunoexpression of this protein in 
oral epithelium of mice trated by 4NQO. It also corrobora-
tes the speculated protective role of MT against other oral 
carcinogens (e. g. tobacco products). In fact, smoking has 
been associated with stimulation of MT production in vitro 
and in vivo (21). Increased MT expression has been shown 
in gingival tissues of smokers (22). Extrapolation of our 
results suggests a protective function for MT in humans 
since chemical toxicity is the most important mutagenic 
mechanism associated with intra-oral carcinogenesis.
DNA is a target molecule for 4NQO and its metabolites which 
form adducts within the genome favoring mutagenesis and 
tumour formation (5). Oxidative stress is thought to play a pro-
carcinogenic role in carcinomas caused by 4NQO (23,24). MT 
can confer protection against oxidative damage on a specific 
target, such as DNA (25,26). This could help to explain the 
observation of a higher number of immunoreactive cells with 
cytoplasmic and nuclear staining in the experimental group 
compared to controls. In this case, we suggest the combined 
high nuclear concentration of MT and its excellent hydroxyl 
scavenger properties confer protection to DNA from hydroxyl 
radical attack.
Several lines of studies indicate that MT plays a role in 
carcinogenesis (16,25,27): MT genes are highly inducible by 
a variety of stress conditions which is a typical response of 
cellular defense (12); MT presents multiple tiol groups which 
render a strong scavenger property to this molecule, not only 
to metals, to which MT binds avidly, but also to metabolites 
that may be carcinogenic, such as 4NQO adducts (12,16). 
The extent and dynamic of this binding could determine 
to some extent the vulnerability to tumour development. 
Finally, other studies have demonstrated a possible role for 
MT in modulating spontaneous mutagenesis (28). In this 
case, low MT expression in tissues might be a risk factor 
for cancer.
The present results show an increase of MT immunohis-
tochemical staining in oral mucosa of  mice exposed to 
carcinogen 4NQO. This may suggest a protective function 
for MT in early stages of carcinogenesis in this model.
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